Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) Other Non Operating Income (2020 - 2025)

Mirum Pharmaceuticals (MIRM) has 6 years of Other Non Operating Income data on record, last reported at -$2.6 million in Q4 2025.

  • For Q4 2025, Other Non Operating Income fell 1220.78% year-over-year to -$2.6 million; the TTM value through Sep 2025 reached $2.8 million, up 105.42%, while the annual FY2024 figure was $1.2 million, 142.95% up from the prior year.
  • Other Non Operating Income reached -$2.6 million in Q4 2025 per MIRM's latest filing, down from $395000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $2.1 million in Q1 2025 and bottomed at -$53.0 million in Q4 2023.
  • Average Other Non Operating Income over 5 years is -$2.6 million, with a median of -$25500.0 recorded in 2021.
  • The widest YoY moves for Other Non Operating Income: up 788.54% in 2023, down 5458.45% in 2023.
  • A 5-year view of Other Non Operating Income shows it stood at $565000.0 in 2021, then plummeted by 268.67% to -$953000.0 in 2022, then plummeted by 5458.45% to -$53.0 million in 2023, then soared by 100.44% to $231000.0 in 2024, then tumbled by 1220.78% to -$2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non Operating Income were -$2.6 million in Q4 2025, $395000.0 in Q3 2025, and $86000.0 in Q2 2025.